For inhibiting platelet aggregation, aspirin (catalog no. J20171021, Bayer) at 30 mg/kg or warfarin (catalog no. H31022123, SINE) at 30 mg/kg was given orally once per day to each mouse for 10 days. Distilled water was used as a control. For metastasis inhibition, a selective GRP75 inhibitor MKT-077 (catalog no. A12388, AdooQ Bioscience) at 15 mg/kg was intraperitoneally injected once per day into each mouse. DMSO (catalog no. MB2505, Meilunbio) was used as a control. For in vitro platelet activation, freshly isolated mouse or human platelets were treated with ADP (catalog no. MB1706, Meilunbio), collagen (catalog no. MB5213, Meilunbio), thrombin (catalog no. MB1368, Meilunbio), ionomycin (catalog no. MB7511, Meilunbio), and arachidonic acid (AA, catalog no. MB6012, Meilunbio). In some experiments, a GRP75 inhibitor MKT-077 (catalog no. A12388, AdooQ Bioscience) at 20 mmol/L was pretreated for 30 minutes prior to agonist stimulation.
Wu B., Ye Y., Xie S., Li Y., Sun X., Lv M., Yang L., Cui N., Chen Q., Jensen L.D., Cui D., Huang G., Zuo J., Zhang S., Liu W, & Yang Y. (2021). Megakaryocytes Mediate Hyperglycemia-Induced Tumor Metastasis. Cancer research, 81(21).
+ Open protocol